Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization remains negative
Q3 FY2026 depreciation & amortization was $0, compared with $304K a year earlier. Trailing-twelve-month depreciation & amortization was $775K. Over 3 fiscal years it compounded at -7.2% a year.
Context
- Depreciation & amortization amounted to 0.7% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $193.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- -14.4%
- 4-year CAGR
- +3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | -14.4% |
| FY2024 | 2024-12-31 | 1.56M | -11.1% |
| FY2023 | 2023-12-31 | 1.76M | +5.1% |
| FY2022 | 2022-12-31 | 1.67M | +44.4% |
| FY2021 | 2021-12-31 | 1.16M | — |
Depreciation & Amortization vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's LTM Sep 2026 depreciation & amortization of $775K is the 6th highest of the 11 companies compared; the peer median is $735K.
- Its year-over-year change of -46.5% is the 9th highest of 11, against a peer median of -7.2%.
- Depreciation & amortization amounts to 0.3% of revenue for RYTM, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $134.49M | +62.6% | -7.9% | 0.0% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Jun 2026 | $1.92M | +74.2% | +141.5% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.25M | -21.5% | — | 1.3% |
| LTM Mar 2026 | $1.02M | -43.2% | +26.8% | — | |
| LTM Sep 2026 | $775K | -46.5% | -7.2% | 0.3% | |
| LTM Jun 2026 | $450K | +7.1% | +14.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K | +39.4% | +64.2% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K | +39.8% | +18.2% | 2.3% |
| LTM Mar 2026 | $98.72K | -73.7% | -18.9% | 0.8% | |
BLTEBelite Bio, Inc | LTM Sep 2026 | $117 | -99.9% | +32.8% | — |
| Peer median (excluding RYTM) | $735K | -7.2% | +18.2% | 1.3% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.15M | 23.64M | 77.43M | 130.13M | 189.76M |
| Cost of Revenue | 599K | 2.13M | 9.3M | 13.37M | 19.49M |
| Gross Profit | 2.56M | 21.51M | 68.13M | 116.76M | 170.27M |
| Gross Margin | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% |
| Research & Development | 104.13M | 108.63M | 134.95M | 237.96M | 167.34M |
| Selling, General & Admin | 68.49M | 92.03M | 117.53M | 144.3M | 194.94M |
| Operating Expenses | 172.61M | 200.66M | 252.48M | 382.26M | 362.28M |
| Depreciation & Amortization | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M |
| EBITDA | (68.45M) | (174.25M) | (168.46M) | (238.09M) | (174.12M) |
| EBITDA Margin | -2170.4% | -737.1% | -217.6% | -183.0% | -91.8% |
| Operating Income | (170.06M) | (179.16M) | (184.36M) | (265.5M) | (192.02M) |
| Operating Margin | -5391.9% | -757.9% | -238.1% | -204.0% | -101.2% |
| Interest Income | 447K | 4.03M | 13.95M | 14.71M | 15.29M |
| Interest Expense | 0 | 5.2M | 13.89M | 20.6M | 20.58M |
| Other Income / Expenses | 100.45M | (1.96M) | 243K | 5.25M | (4.03M) |
| Income Before Tax | (69.61M) | (181.12M) | (184.11M) | (260.26M) | (196.04M) |
| Pre-Tax Margin | -2207.1% | -766.2% | -237.8% | -200.0% | -103.3% |
| Income Tax Expense | 0 | 0 | 564K | 346K | 497K |
| Net Income | (69.61M) | (181.12M) | (184.68M) | (260.6M) | (196.54M) |
| Net Margin | -2207.1% | -766.2% | -238.5% | -200.3% | -103.6% |
| EPS (Basic) | (1.37) | (3.51) | (3.20) | (4.34) | (3.11) |
| EPS (Diluted) | (1.37) | (3.51) | (3.20) | (4.34) | (3.11) |
| Weighted Avg Shares | 49.6M | 52.12M | 57.67M | 61M | 64.98M |
| Weighted Avg Shares (Diluted) | 49.6M | 52.12M | 57.67M | 61M | 64.98M |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.